Epistem is a leading company providing innovative services to accelerate drug development programmes. We provide preclinical and clinical services that can either be classified by technique or by therapeutic area and include the following:
Services by Technique
- Genetics testing (DNA genotyping and RNA gene expression) - NGS (Illumina), Microarray (Affymetrix and Agilent) and qPCR (high throughput Fluidigm platform and Roche Lightcyclers)
- Histology - GCLP compliant sample assessments and IHC optimisation and validation services, RNAScope assessments on multiple platforms (including Ventana and Aperio platforms)
- FACS - Multiple BD and Miltenyi platforms (including Miltenyi MACS Quant (3 laser allowing for 8 colors), 2 x BD LSR Fortessa, BD LSR-II, BD FACS Canto-II, BD FACS Verse, BD Influx, BD FACS Aria Fusion
- Preclinical Imaging - Optical imaging, PET-CT & MRI
- Microbiome testing
- ELISA and multiplexed (Luminex) protein assays
Preclinical Research Services
- IBD Models - DSS and T-cell transfer colitis models as well as a TNBS model for acute colitis
- Arthritis - collagen induced and air pouch models
- Psoriasis - in vitro and in vivo models including the imiquimod-induced model
- Wound Healing - in vitro and in vivo models (in vitro: cell proliferation, migration and wound contraction; in vivo: acute excisional and incisional models)
- Skin - monolayer assays, human living skin equivalent, organ culture, skin xenografts, hair growth assays
- Organoid assays and ex vivo pathogenic T cell assays
- Oncology - Cancer stem cell assay, immuno-oncology models, angiogenesis models, subcutaneous xenografts, orthotopic models (acute myeloid leukaemia, acute lymphoblastic leukaemia, solid tumour orthotopic models), Min+/- model, target validation assays, therapy side effect assays, cytotoxicity assays (GI Tox, mucositis, alopecia, bone marrow tox)